Long-term outcomes of frontline imatinib therapy for chronic myeloid leukemia in China

BACKGROUND: Imatinib is the first-line therapy recommended for chronic myeloid leukemia (CML) patients in China. We reported a long-term follow-up study of patients on imatinib as first-line treatment for chronic phase (CP) CML to provide an important reference for the actual clinical treatment regi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Fang, Yuan, Guolin, Li, Qiang, Cui, Zheng, Li, Weiming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185871/
https://www.ncbi.nlm.nih.gov/pubmed/37205184
http://dx.doi.org/10.3389/fonc.2023.1172910

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10185871/
https://www.ncbi.nlm.nih.gov/pubmed/37205184
http://dx.doi.org/10.3389/fonc.2023.1172910

Ejemplares similares